For over 25 years, Medicover Genetics has pioneered advancements in genetic testing and counselling.
We offer a constantly evolving portfolio of tests for thousands of indications, empowering patients and healthcare providers to make informed medical decisions.
Together, we can provide accurate, fast, and cost-efficient solutions to benefit patients all over the world.
Our oncology portfolio offers a wide range of tests that empower healthcare providers to identify the best solution for their patients.
A group of gene panels linked to the onset of different types of hereditary cancer, including one comprehensive panel
Gene panels to identify genetic variants associated with cancer susceptibility, including 19 hereditary cancer panels that test for up to 62 genes
Diagnostic solution combining histopathology and genetic tests to diagnose a tumor. The results can provide information on the prognosis and severity of the cancer and treatment options for the patient
Genetic analysis of a tumor’s molecular characteristics using a proprietary target capture enrichment technology. Our panels include 2 comprehensive, 6 cancer-specific and 5 gene-focused tumor profile panels.
Our liquid biopsy portfolio can provide guidance for targeted therapies safely, non-invasively and precisely, overcoming some of the challenges associated with tumor biopsy
Our rare disease portfolio offers diagnostic panels divided into test categories based on the organ or tissue that is most affected by the syndrome
Gene panels categorized into 4 different cardiac and aortic disease groups, including 3 comprehensive panels
Gene panels include 7 disease category panels and 1 comprehensive panel (292 genes)
Diagnostic solution combining 2 or more genetic testing methodologies to diagnose children with global developmental delay
Covers the major categories of inherited metabolic diseases and is offered as a single, detailed panel of 223 genes involved in metabolic pathways.
Genetic testing during a reproductive lifetime
Testing for the carrier status of autosomal recessive disorders or X-linked disorders
Detection of the most common fetal aneuploidies and microdeletions (all included in VERAgene as well) which occur more frequent with advanced maternal age. VERACITY has been validated by several clinical studies for single and twin pregnancies, and can also be used in pregnancies conceived through in-vitro fertilization (IVF)
Simultaneous screen for aneuploidies (included in VERACITY), microdeletions and monogenic diseases provides a comprehensive solution to prospective parents using a single test. Genetic diseases screened in VERAgene are associated with significant impact on life quality
With non-invasive fetal Rhesus factor (RhD) determination, RhD negative pregnant women can have their blood tested to determine the RhD of their unborn child
Preimplantation genetic testing to optimize IVF success
Tests for genetic changes (mutations) associated with infertility, thereby, giving personalized insight for family planning
Understand how whole exome sequencing can help diagnose cases that do not fit into a phenotypic category from our rare disease panels
Genetic testing and reporting of a fixed number of genes for gamete donors and/or recipients, as per prespecified panel.
The attached document details instructions for the collection, transportation, and storage of samples for genetic testing and is only applicable for the stated products and services received via envelope.
Improving fertility outcomes with endometrial microbial testing
Enabling personalized treatments for safer, more effective care through genetic insights
